We aim to demystify the intricate EGFR-HER3 relationship, evaluate HER3-focused therapeutic strategies, and champion the potential of HER3 inhibition as a novel approach against EGFR-driven NSCLC. The gene discussed is ERBB3; the disease is non-small cell lung carcinoma.